Scholarlink

<p>The intrinsic radio-resistance of pancreatic cancer cells significantly hinders therapeutic efficacy. However, the precise molecular mechanisms underlying this resistance remain inadequately understood and warrant further investigation. Here, using the high-throughput metabolic CRISPR library screening and RNA sequencing, we identified an ATPase Plasma Membrane Ca<sup>2+</sup> Transporting 4 (ATP2B4) as a novel molecular contributor to radiotherapy resistance in pancreatic cancer both in vitro and in vivo. Functionally, micrococcal nuclease assay, drug rescue assays, along with overexpression and silencing experiments, revealed that knockout of ATP2B4 induced chromatin decompaction through the downregulation of histone H1.0, thereby exacerbating DNA damage and increasing RT-induced cell apoptosis. Mechanistically, TurboID-based mass spectrometry and immunoprecipitation (IP) demonstrated that ATP2B4 stabilized ELAVL1, maintaining its function, which further regulated the mRNA stability of histone H1.0. Taken together, our findings identified ATP2B4 as a key regulator of chromatin compaction and DNA damage response, positioning it as a potential biomarker for predicting RT outcomes and a promising therapeutic target for overcoming RTR.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ATP2B4 driven chromatin compaction exacerbates pancreatic cancer radiotherapy resistance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月25日

查看全文
  • Yuyu Luo,
  • Wei Jiang,
  • Yanfang Liu,
  • Qinghua Li,
  • Yuanfei Chen,
  • Shiwan Lin,
  • Hsiang-i Tsai,
  • Lirong Zhang,
  • Dongqing Wang,
  • Xiang Liao,
  • Haitao Zhu

摘要

The intrinsic radio-resistance of pancreatic cancer cells significantly hinders therapeutic efficacy. However, the precise molecular mechanisms underlying this resistance remain inadequately understood and warrant further investigation. Here, using the high-throughput metabolic CRISPR library screening and RNA sequencing, we identified an ATPase Plasma Membrane Ca2+ Transporting 4 (ATP2B4) as a novel molecular contributor to radiotherapy resistance in pancreatic cancer both in vitro and in vivo. Functionally, micrococcal nuclease assay, drug rescue assays, along with overexpression and silencing experiments, revealed that knockout of ATP2B4 induced chromatin decompaction through the downregulation of histone H1.0, thereby exacerbating DNA damage and increasing RT-induced cell apoptosis. Mechanistically, TurboID-based mass spectrometry and immunoprecipitation (IP) demonstrated that ATP2B4 stabilized ELAVL1, maintaining its function, which further regulated the mRNA stability of histone H1.0. Taken together, our findings identified ATP2B4 as a key regulator of chromatin compaction and DNA damage response, positioning it as a potential biomarker for predicting RT outcomes and a promising therapeutic target for overcoming RTR.